Summit Therapeutics Inc. Comprehensive Income
Summit Therapeutics Inc. (SMMT) reported Comprehensive Income of -GBP 4.92 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Income Statement › Unrealized Gains
ifrs-full:ComprehensiveIncome · last filed 2020-06-02
- Summit Therapeutics Inc. comprehensive income for the quarter ending 2020-03-31 was -4.92M GBP.
- Summit Therapeutics Inc. comprehensive income for the quarter ending 2019-10-31 was -7.05M GBP.
- Summit Therapeutics Inc. comprehensive income for the quarter ending 2019-07-31 was -5.14M GBP, a 119.29% decline year-over-year.
- Summit Therapeutics Inc. comprehensive income for the quarter ending 2019-04-30 was -4.02M GBP.
| Period end | Comprehensive Income 3 month | Comprehensive Income 3 month as first filed | Comprehensive Income 6 month | Comprehensive Income 6 month as first filed | Comprehensive Income 9 month | Comprehensive Income 9 month as first filed | Comprehensive Income 11 month | Comprehensive Income 12 month | Comprehensive Income 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -4.92M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | -22.03M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | -7.05M GBP 6-K · filed 2019-12-17 | -12.19M GBP derived: sum of 2 quarters · filed 2019-12-17 | -16.21M GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | -5.14M GBP 6-K · filed 2019-10-11 | -9.16M GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | -4.02M GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | -5.34M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | -5.17M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -13.30M GBP derived: sum of 2 quarters · filed 2020-04-30 | 13.35M GBP derived: sum of 3 quarters · filed 2020-04-30 | 7.51M GBP 20-F · filed 2020-04-30 | 7.55M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | -8.13M GBP 6-K · filed 2019-12-17 | 18.52M GBP derived: sum of 2 quarters · filed 2019-12-17 | 12.68M GBP 6-K · filed 2019-12-17 | 12.71M GBP 6-K · filed 2018-12-11 | 1.42M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-07-31 | 26.65M GBP 6-K · filed 2019-10-11 | 20.81M GBP 6-K · filed 2019-10-11 | 20.83M GBP 6-K · filed 2018-09-20 | 9.55M GBP derived: sum of 3 quarters · filed 2020-04-30 | 8.69M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-04-30 | -5.83M GBP 6-K · filed 2019-06-12 | -5.83M GBP 6-K · filed 2018-06-05 | -17.09M GBP derived: sum of 2 quarters · filed 2020-04-30 | -17.96M GBP derived: sum of 3 quarters · filed 2020-04-30 | -21.23M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | -11.26M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -12.12M GBP derived: sum of 2 quarters · filed 2020-04-30 | -15.39M GBP derived: sum of 3 quarters · filed 2020-04-30 | -20.17M GBP 20-F · filed 2020-04-30 | -7.14M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | -862.00K GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | -4.14M GBP derived: sum of 2 quarters · filed 2018-12-11 | -8.91M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | -3.27M GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | -8.05M GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | -4.78M GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | -21.34M GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | -20.18M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |